New cancer therapies raise new safety concerns

Oncology researchers, and drug company executives, are reportedly concerned about the safety of a new generation of immunotherapies, according to Reuters. The news service writes that in clinical trials there have been concerns about both CART (chimeric antigen receptor T cells) therapies and bispecific antibodies, which can cause the “potentially fatal buildup of debris from killed tumor cells and damage to health tissue.” Executives and researchers alike are concerned that this collateral damage could hinder regulatory approval if left uncontrolled. Amgen's Blincyto was the first FDA-approved bispecific antibody.


Next Article in Pharmaceutical